Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia
Titel:
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia
Auteur:
Hill, Brian T. Ma, Shuo Zent, Clive S. Baran, Andrea M. Wallace, Danielle S. Advani, Anjali Winter, Allison Winter, Jane Gordan, Leo Karmali, Reem Liesveld, Jane L. Mulford, Deborah A. Rowland, Chris Bui, Andrew Sportelli, Peter Miskin, Hari P. Weiss, Michael S. Friedberg, Jonathan W. Barr, Paul M.